Financial News · Live Terminal

Page 291 of 352

Oppenheimer Adjusts Definium Therapeutics PT to $40 From $25, Maintains Outperform Rating

Definium Therapeutics, Inc. (DFTX) has an average rating of Buy and mean price target of $38.87, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $22.79, Change: $-0.29, Percent Change: -1.26%

Financial News · Live Terminal

Oppenheimer Adjusts Definium Therapeutics PT to $40 From $25, Maintains Outperform Rating

UBS Adjusts Price Target on Tapestry to $142 From $141, Maintains Neutral Rating

Oppenheimer Adjusts Boston Scientific Price Target to $90 From $100, Maintains Outperform Rating

UBS Adjusts Price Target on Raymond James Financial to $166 From $158, Maintains Neutral Rating

Deutsche Bank Raises Price Target on Texas Instruments to $240 From $205, Keeps Hold Rating

Ultra Clean Says Clarence Granger to Step Down as Chairman, Tom Edman Tapped as Successor

UBS Adjusts Price Target on Fair Isaac to $1,150 From $1,200, Maintains Neutral Rating

Tempus AI, USC Form Strategic Precision Medicine Partnership

Deutsche Bank Lifts Price Target on Lam Research to $325 From $300, Keeps Buy Rating

Oppenheimer Adjusts Akamai Technologies Price Target to $130 From $115, Maintains Outperform Rating

UBS Adjusts Price Target on Thomson Reuters to $183 From $215, Maintains Buy Rating

Tetra Tech Selected for Netherlands Wastewater Treatment Project

Deutsche Bank Trims Price Target on AT&T to $32 From $33, Keeps Buy Rating

UBS Adjusts Price Target on Masco to $97 From $96, Maintains Buy Rating

UBS Adjusts Price Target on TE Connectivity to $261 From $272, Maintains Buy Rating

Bed Bath & Beyond to Overhaul The Container Store Locations in Integration Push

Deutsche Bank Cuts Price Target on Medpace Holdings to $425 From $480, Keeps Hold Rating

UBS Adjusts Price Target on Knight-Swift Transportation Holdings to $79 From $66, Maintains Buy Rating

Equinix to Support SpinLaunch's Meridian Space Satellite Constellation

UBS Adjusts Price Target on Healthcare Services to $27 From $25, Maintains Buy Rating

Oppenheimer Adjusts Definium Therapeutics PT to $40 From $25, Maintains Outperform Rating

UBS Adjusts Price Target on Tapestry to $142 From $141, Maintains Neutral Rating

Oppenheimer Adjusts Boston Scientific Price Target to $90 From $100, Maintains Outperform Rating

UBS Adjusts Price Target on Raymond James Financial to $166 From $158, Maintains Neutral Rating

Deutsche Bank Raises Price Target on Texas Instruments to $240 From $205, Keeps Hold Rating

Ultra Clean Says Clarence Granger to Step Down as Chairman, Tom Edman Tapped as Successor

UBS Adjusts Price Target on Fair Isaac to $1,150 From $1,200, Maintains Neutral Rating

Tempus AI, USC Form Strategic Precision Medicine Partnership

Deutsche Bank Lifts Price Target on Lam Research to $325 From $300, Keeps Buy Rating

Oppenheimer Adjusts Akamai Technologies Price Target to $130 From $115, Maintains Outperform Rating

UBS Adjusts Price Target on Thomson Reuters to $183 From $215, Maintains Buy Rating

Tetra Tech Selected for Netherlands Wastewater Treatment Project

Deutsche Bank Trims Price Target on AT&T to $32 From $33, Keeps Buy Rating

UBS Adjusts Price Target on Masco to $97 From $96, Maintains Buy Rating

UBS Adjusts Price Target on TE Connectivity to $261 From $272, Maintains Buy Rating

Bed Bath & Beyond to Overhaul The Container Store Locations in Integration Push

Deutsche Bank Cuts Price Target on Medpace Holdings to $425 From $480, Keeps Hold Rating

UBS Adjusts Price Target on Knight-Swift Transportation Holdings to $79 From $66, Maintains Buy Rating

Equinix to Support SpinLaunch's Meridian Space Satellite Constellation

UBS Adjusts Price Target on Healthcare Services to $27 From $25, Maintains Buy Rating